Sign in Subscribe
Pharmaceutical industry

Keryx Biopharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

Strategic Insights

— 1 min read

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, Inc., will be presenting at the 13th Annual BIO CEO & Investor Conference in New York City on February 14th. The presentation will focus on the Company's pipeline of life-threatening disease treatments, including KRX-0401 (perifosine) for cancer and renal disease, and Zerenex (ferric citrate) for hyperphosphatemia in patients with end-stage renal disease.

Key Takeaways:

  • Keryx Biopharmaceuticals is focused on developing life-threatening disease treatments, including cancer and renal disease.
  • The Company is developing two primary pipeline products: KRX-0401 (perifosine) and Zerenex (ferric citrate).
  • KRX-0401 has demonstrated clinical efficacy in several tumor types, both as a single agent and in combination with other therapies.
  • KRX-0401 is in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 development for several other tumor types.
  • Zerenex (ferric citrate) is an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.
  • The Phase 3 clinical program of Zerenex in the treatment of hyperphosphatemia in patients with end-stage renal disease is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.
  • Keryx Biopharmaceuticals is headquartered in New York City and has a strong pipeline of life-threatening disease treatments.

Statistics:

  • Keryx Biopharmaceuticals is developing two primary pipeline products: KRX-0401 (perifosine) and Zerenex (ferric citrate).
  • KRX-0401 has demonstrated safety and clinical efficacy in several tumor types, including refractory advanced colorectal cancer and multiple myeloma.
  • Zerenex (ferric citrate) has the capacity to bind to phosphate and form non-absorbable complexes, making it a potential treatment for hyperphosphatemia in patients with end-stage renal disease.
  • The Phase 3 clinical program of Zerenex is being conducted under a SPA agreement with the FDA.
  • KRX-0401 is in Phase 3 development for refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 development for several other tumor types.

Sources:

  • Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX)
  • Biotech Week editors from staff and other reports. Copyright 2011, Biotech Week via NewsRx.com.

Read more